TABLE 2.
Reported cardiovascular-related outcomes in studies comparing single-pill combination and free-dose combination regimens
| n/N [%] | |||||||||
| 1st Author (year) [REF], study type | Treatment (SPC/free) | Treatment details | Hypotension | Oedema | Syncope | Angina | MI | HF | Stroke |
| Verma (2018) [14] – Obs | SPC | NR | NR | NR | NR | NR | 46/8258 (0.6) | 19/8261 (0.2) | 39/8243 (0.5) |
| Free | NR | NR | NR | NR | NR | 34/6322 (0.5) | 11/6330 (0.2) | 26/6320 (0.4) | |
| Webster (2018) [46] – RCT | SPC | tel/amlo/chlo | 2 (0.6) | 6 (1.7) | 18 (5.2) | 11 (3.2) | NR | NR | NR |
| Free | NR | 2 (0.6) | 5 (1.4) | 10 (2.8) | 10 (2.8) | NR | NR | NR | |
| Nedogoda (2017) [38] – RCT | SPC | per/ind/amlo | NR | NR | NR | NR | NR | NR | NR |
| Free (2 pills) | (per/ind) + amlo | 1 (1.3) | NR | NR | NR | NR | NR | NR | |
| Tung (2015) [44] – Obs | SPC | amlo/val | NR | NR | NR | NR | 19 (0.58) | 70 (2.12) | 197 (5.97) |
| Free | ARB + CCB | NR | NR | NR | NR | 122 (0.92) | 431 (3.26) | 864 (6.54) | |
| Panjabi (2013) [39] – Obs | Mix (2 pills) | amlo/HCTZ + ARB | NR | NR | NR | NR | 55 (1.37) | 242 (6.04) | 66 (1.65) |
| Free (3 pills) | amlo + HCTZ + ARB | NR | NR | NR | NR | 17 (1.27) | 90 (6.74) | 27 (2.02) | |
| Mix (2 pills) | amlo/HCTZ + ACEi | NR | NR | NR | NR | 68 (1.12) | 282 (4.64) | 96 (1.58) | |
| Free (3 pills) | amlo + HCTZ + ACEi | NR | NR | NR | NR | 40 (1.32) | 147 (4.83) | 56 (1.84) | |
| Mix (2 pills) | amlo/HCTZ + BB | NR | NR | NR | NR | 30 (0.49) | 33 (5.42) | 11 (1.81) | |
| Free (3 pills) | amlo + HCTZ + BB | NR | NR | NR | NR | 20 (1.64) | 101 (8.29) | 26 (2.13) | |
ACEi, angiotensin-converting enzyme inhibitor; amlo, amlodipine; ARB, angiotensin 1 receptor (AT1) blocker; BB, beta blockers; BP, blood pressure; CCB, calcium channel blocker; chlo, chlorthalidone; HCTZ, hydrochlorothiazide; HF, heart failure; ind, indapamide; MI, myocardial infarction; per, perindopril; tel, telmisartan; val, valsartan.